About the AuthorMy name is Mark Senak. I’m a lawyer and I work at the international communications firm FleishmanHillard in New York. For the past several years, I have been consulting with pharmaceutical and biologic companies that are engaged in the process of bringing new drugs to market.
My ProfileI am an authority on regulatory aspects of communications and medical products, with particular emphasis on pre-approval communications; strategist to help pharma and biotech companies prepare best case for advisory committee approval; and counselor in issues and crisis management. I am a frequent speaker on various aspects of same - drug development, promotion, reimbursement and new media in a highly regulated environment. Author of books, newspaper and magazine pieces related to drug marketing and promotion as well as HIV specialty pieces. And of course... blogger!
About This BlogEye on FDA is published by Mark Senak of FleishmanHillard's Washington, D.C. office. The thoughts and ideas in this blog and postings are strictly my own and are not screened by my employer. Everything posted on this blog is my personal opinion and does not necessarily represent the views of FleishmanHillard or its clients.
Posts by Date
My Favorite Dogs
Category Archives: Crisis Communications
Election cycle aside, it is going to be a rough summer. As things stand, this will likely become the summer of Zika as the country faces a growing potential for dealing with transmission inside the U.S. and abroad. As the … Continue reading
A few months ago in early February, a Congressman attended a meeting of the House Ways and Means Committee. At a little after 2PM, he cast a vote on an issue before the committee. Just shy of a half hour … Continue reading
A lot of the focus on social media is about marketing of brands and products. But what about crisis communications? The truth is – the lack of any digital strategy with respect to crisis communications planning can have a profoundly … Continue reading
On Friday, I had the opportunity to provide some thoughts to Matthew Perrone of the Associated Press in relation to an article he was writing about the recent "early communication" from the FDA regardin GlaxoSmithKline's Over-the-Counter weight loss product alli. … Continue reading